MEFV and histiocytic sarcoma: Similarly, a retrospective review including 109 complex HS patients, defined as having Hurley stage III (severe disease) and/or other inflammatory symptoms, revealed that 38% of them harboured MEFV pathogenic variants, suggesting that MEFV mutations may contribute to the pathogenesis of HS and its complex phenotypes [81].